It is important to recognize this group of patients because of higher risk of thrombosis demonstrated in 66 JAK2-mutated patients < 40 years of age compared to a control group of 97 cases with overt PV as there was less frequent use of phlebotomies or cytoreductive treatment for those so called mPV [14]. This evidence concerns the gene JAK2 and acquired polycythemia vera.